EZH2 and myeloproliferative disorder: However, in 2010, loss-of-function mutations of EZH2 were observed in myeloid malignancies, most frequently affecting patients with MDS/MPN (10–13%), myelofibrosis (13%) and various MDS entities (6%) [20,21].